Logo image
Back
Kidney transplant from HCV viremic donors to HCV-negative recipients and risk for de novo donor specific antibodies and acute rejection
Journal article   Peer reviewed

Kidney transplant from HCV viremic donors to HCV-negative recipients and risk for de novo donor specific antibodies and acute rejection

Reem Daloul, Kalathil Sureshkumar, Kendra Schnelle, Lauren Von Stein, April Logan and Todd Pesavento
Clinical transplantation, v 37(2), e14895
Feb 2023
DOI: https://doi.org/10.1111/ctr.14895
PMID: 36580971
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Graft Rejection - epidemiology Graft Survival Hepatitis C - etiology Humans Kidney Transplantation - adverse effects Retrospective Studies Tissue Donors Transplant Recipients Viremia - etiology Antibodies
Kidney transplantation from HCV-viremic donors into uninfected recipients is associated with excellent short-term outcomes. However, concerns regarding an increased risk for the development of de novo donor specific antibodies (DSA) and acute rejection have been raised in single center reports. A retrospective study of HCV-negative kidney-only transplant recipients between 2018 and 2020. Patients were grouped based on the donor HCV status into group 1; HCV-viremic donors, and group 2; HCV-negative donors. Inverse probability of treatment weighting (IPTW), with weights derived from the propensity score, were used to estimate the effect of donors' HCV-viremia on the recipients. The primary objective was to compare the 1-year incidence of de novo DSA. Secondary outcomes included group comparison of the incidence of biopsy proven acute rejection (BPAR), 1-year patient and allograft survival, and 1-year renal allograft function. A total of 71 patients were included in the HCV NAT+ group, and 440 in the HCV- negative group. One-year incidence of de novo DSA was higher in the HCV NAT+ group in the IPTW weighted analysis (19% vs. 9%, p = .02). In the unweighted analysis, BPAR occurred in 7% of recipients in the HCV NAT+ group, compared to 3% in the control group (p = .06). However, due to the low event rate in the in the IPTW weighted groups, a statistical significance test could not be performed. Average estimated GFR was higher in the HCV-viremic group at 3 months (61 vs. 53 ml/min/1.73 mp = .002), but comparable at 6 (59 vs. 56 ml/min/1.73 m , p = .31) and 12 months (60 vs. 55 ml/min/1.73 m , p = .07). Patient and allograft survival were comparable between the two groups. Kidney transplant from HCV-viremic donors was associated with an increased risk for the development of post-transplant de novo DSA in the first year after transplantation, but no difference in patient and graft survival.

Metrics

5 Record Views
1 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Surgery
Transplantation
Logo image